Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
Nisha Muralidharan, Ramasamy Sakthivel, D. Velmurugan, M. Michael Gromiha
Abstract
Click to increase image sizeClick to decrease image size AcknowledgementsWe thank the Department of Biotechnology and Indian Institute of Technology Madras for computational facilities. We wish to acknowledge Dr. C. Ramakrishnan, Dr. S. Anusuya, S. Akila Parvathy Dharshini and Dr. A. Mary Thangakani for fruitful discussions.Disclosure statementNo potential conflict of interest was reported by the authors.TableDownload CSVDisplay TableAdditional informationFundingThe work is partially supported by the Department of Biotechnology, Government of India to MMG.
Topics & Concepts
RepurposingRitonavirLopinavirCoronavirus disease 2019 (COVID-19)Drug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Government (linguistics)Virology2019-20 coronavirus outbreakLopinavir/ritonavirMedicinePharmacologyTraditional medicineDrugBiologyInternal medicineViral loadPhilosophyHuman immunodeficiency virus (HIV)OutbreakDiseaseLinguisticsInfectious disease (medical specialty)Antiretroviral therapyEcologyComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchTuberculosis Research and Epidemiology